Blood Test Predicts Survival of Young Patients with Leukemia

Anderson Cancer Center (Houston, TX, USA) presented their study of leukemia patients at the American Society of Pediatric Hematology Oncology's annual meeting on May 5, 2007, in Toronto, Canada.
A review of young leukemia patients over the past decade has shown that the absolute lymphocyte count (ALC), a measure of normal immune cells found on every complete blood count report, is a powerful predictor of survival for young patients with leukemia. According to the American Cancer Society, the average rate of survival for pediatric patients with acute myelogenous leukemia (AML) is close to 50%. However, scientists have found that using the ALC count on day 15 after initial chemotherapy treatment can significantly predict which patients are likely to relapse and those who will not. This prediction may help physicians decide how aggressively to treat a leukemia patient. In addition, it may direct researchers in developing therapies to increase a patient's ability to battle the leukemia cells

The scientists studied 171 patients with either AML or acute lymphocytic leukemia (ALL), 21 years or younger, who had begun treatment at M.D. Anderson between 1995 and 2005. The statistics showed significant differences in survival rates in multiple analyses. The results from the study showed that AML patients who had a low lymphocyte count on day 15 of treatment had a five-year overall survival chance of only 28%. However, patients with higher lymphocyte counts on day 15 had a much better overall survival rate of 85%.

For patients with ALL, the most common form of childhood leukemia, those children and young adults with a high ALC count on day 15 had an 87% six-year overall survival rate while those with a low lymphocyte count had a 55% overall survival rate.

Investigators at the Children's Cancer Hospital plan to continue their study by following newly diagnosed patients, and have begun a new study that analyzes the subsets of lymphocytes to see which ones have the most impact on prognosis. They hope their findings will be used to help physicians worldwide make decisions on how aggressively to treat their patients.


Related Links:
M.D. Anderson Cancer Center